Identifying biomarkers for autoimmune diseases affecting the nervous system
Biomarkers of Neurological Autoimmune Diseases
This study is trying to find specific markers in the blood of people with autoimmune diseases affecting the nervous system, like Multiple Sclerosis, to help with early diagnosis and better treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tongji Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Wuhan) |
| Trial ID | NCT06502015 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on autoimmune diseases of the nervous system, including conditions like Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis. The researchers aim to recruit patients diagnosed with these diseases to discover biomarkers that can aid in early diagnosis, disease monitoring, and personalized treatment. By utilizing advanced techniques such as proteomics and metabolomics, the study seeks to enhance understanding of these complex conditions and improve patient outcomes. The study will also include sex and age-matched healthy individuals for comparison.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with specific autoimmune diseases of the nervous system, such as NMOSD, MG, CIDP, MS, and others.
Not a fit: Patients with primary immunodeficiency or secondary central nervous system demyelinating lesions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic tools and personalized treatment options for patients with autoimmune diseases of the nervous system.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for autoimmune diseases, but this approach may offer novel insights into the specific conditions being investigated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis with autoinflammatory diseases of the nervous system, including: Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy(IIM), multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), ect al. * sex and age-matched healthy individuals Exclusion Criteria: * Known history of primary immunodeficiency (innate or acquired). * Patients with severe central nervous system, pulmonary, or other systemic infections. * Patients with secondary central nervous system demyelinating lesions, such as those caused by vasculitis, systemic lupus erythematosus, and Sjögren's syndrome. * Patients with vascular (including hemorrhagic and ischemic), hereditary metabolic, neoplastic, or toxic diseases. * Pregnant or lactating women.
Where this trial is running
Wuhan
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, China (Recruiting)
Study contacts
- Principal investigator: Dai-shi Tian, MD — Tongji Hospital
- Study coordinator: Luo-qi Zhou, MD
- Email: zhouluoqi@tjh.tjmu.edu.cn
- Phone: 86-27-83663337
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.